Sutent 25mg Capsules (Sunitinib): Global Procurement Guide & Clinical Overview:
In the complex field of targeted cancer therapy, Sutent 25mg Capsules (Sunitinib Malate) stand as a breakthrough multi-kinase inhibitor. As a premier pharmaceutical exporter from India, Ernest Oncology (a group of Ernest Pharmaceutical Pvt. Ltd.) provides a streamlined supply chain for this vital medication to the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa.
This comprehensive guide covers the clinical utility of Sutent and essential procurement information for international healthcare providers, pharmacies, and bulk distributors.
What is Sutent 25 mg?
Sutent 25 mg is an oral chemotherapy medication containing the active ingredient Sunitinib. It is classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor. Unlike traditional chemotherapy that attacks all rapidly dividing cells, Sunitinib identifies and blocks specific proteins (kinases) that allow cancer cells to grow and form blood vessels.
Key Therapeutic Indications
Sutent is globally recognized for its efficacy in treating three specific types of cancer:
Gastrointestinal Stromal Tumor (GIST): For patients whose disease has progressed or who cannot tolerate Imatinib (Gleevec).
Advanced Renal Cell Carcinoma (RCC): The primary treatment for advanced or metastatic kidney cancer.
Pancreatic Neuroendocrine Tumors (pNET): For progressive, well-differentiated tumors located in the pancreas.
Clinical Mechanism and Efficacy:
Sutent works through a dual-action process:
Anti-Angiogenesis: It blocks the Vascular Endothelial Growth Factor (VEGF) receptors, essentially cutting off the blood supply that tumors need to survive and expand.
Anti-Proliferation: It inhibits Platelet-Derived Growth Factor (PDGF) receptors, which stops the signals that tell cancer cells to multiply.
Clinical trials in the USA and UK have demonstrated that Sunitinib significantly extends progression-free survival (PFS) in patients with metastatic kidney cancer compared to older cytokine therapies.
Global Procurement & Exporting Excellence:
United States (USA):-
With the high demand for specialized oncology care in the USA, we serve as a reliable bulk supplier from India. We facilitate the procurement of Sutent 25 mg for research institutions and specialty providers, ensuring all documentation for international pharmaceutical trade is strictly maintained.
Why Choose Ernest Oncology as Your Indian Exporter?
Reliable Bulk Supply: We manage high-volume orders for global institutional buyers.
Authenticity Guaranteed: Every pack of Sutent 25mg is sourced through verified channels with full batch traceability.
Optimized Logistics: Expertise in international shipping ensures your medicine arrives safely and on time.
Administration and Safety Information:
Dosage: The standard dose for RCC and GIST is often 50 mg (two 25 mg capsules) once daily for 4 weeks, followed by a 2-week break. For pNET, it is usually taken daily without a break. Always follow the oncologist's specific prescription.
Side Effects: Common reactions may include fatigue, diarrhea, nausea, "Hand-Foot Syndrome" (redness/swelling of palms/soles), and high blood pressure.
Monitoring: Regular blood pressure checks and thyroid function tests are recommended during treatment.
Contact Ernest Oncology—Pharmaceutical Exporter from India
[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD]
If you are a medical procurement officer or a distributor in London, New York, Abu Dhabi, or Sydney, contact us for competitive wholesale pricing and global export solutions.
🌐 Websites:
📧 Email:
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
🔗 Connect on WhatsApp:
